GI360™ profile, an advanced, innovative, comprehensive and clinically-applicable stool profile, utilising multiplex PCR molecular technology, coupled with growth-based culture and ID by MALDI-TOF, sensitive biochemical assays and microscopy to detect and assess the status of pathogens, viruses, parasites and bacteria that may be contributing to acute of chronic gastrointestinal symptoms and disease.
This test includes the additional marker Zonulin.
Elevated serum levels of a zonulin family protein (ZFP) are correlated with abnormal results of the Lactulose Mannitol test; the long-accepted standard for intestinal permeability ("leaky gut"). Elevated levels of ZFP have been associated with metabolic syndrome, obesity, and several autoimmune, inflammatory and neoplastic diseases. Such diseases include Coeliac disease, type I diabetes, juvenile nonalcoholic fatty liver disease, and evidence is accumulating for multiple sclerosis, rheumatoid arthritis, asthma, and inflammatory bowel disease. The test may be used as a clinically equivalent alternative for those who don't want to use the "sugar" load test.
Click for Comparison Guide
This impressive new system incorporates many of the existing popular features of the Comprehensive Stool Analysis with Parasitology which evaluates the status of beneficial bacteria, imbalanced commensal bacteria, pathogenic bacteria, parasites and yeasts. In addition to the PCR testing, if pathogenic cultures are identified, a sensitivity panel is provided to facilitate the selection of pharmaceutical or natural treatment agents. The efficiency of digestion and absorption is measured via faecal elastase, fat, carbohydrate, muscle and vegetable fibres whilst the biomarkers of calprotectin, lysozyme, lactoferrin, white blood cells and mucus can be used to assess inflammation.
This new profile now has the addition of Beta-Glucorinadase
The GI360™ can help to differentiate inflammation associated with inflammatory bowel disease (IBD) from that noted in irritable bowel syndrome (IBS). Humoral immune status of the gut is measured by secretory IgA (sIgA) while the assessment of short-chain fatty acids reflects overall gut health and microbiome balance.
Use this advanced system to identify the causes of gastrointestinal symptoms, autoimmune disease, joint pain, IBD, IBS, inflammation, food sensitivities, nutritional deficiencies and skin conditions.
Maldi-TOF - Dr David Quig, Vice President of Scientific Support
Turnaround time: 10 WORKING DAYS